BMJ Open Respiratory Research (Nov 2023)

Prevalence of reduced lung diffusing capacity and CT scan findings in smokers without airflow limitation: a population-based study

  • ,
  • Joan B Soriano,
  • Juan José Soler-Cataluña,
  • Marc Miravitlles,
  • Julio Ancochea,
  • Elena García Castillo,
  • Miguel Barrueco Ferrero,
  • Begoña Gallego,
  • Ramon Fernandez,
  • Inmaculada Alfageme,
  • Borja G Cosío,
  • Cristina Represas,
  • Pilar de Lucas,
  • Ciro Casanova,
  • Francisco García-Río,
  • José Miguel Rodríguez González-Moro,
  • María Guadalupe Sánchez Herrero,
  • Claudia Valenzuela,
  • Ana Pueyo Bastida,
  • Lourdes Lázaro Asegurado,
  • Luis Rodríguez Pascual,
  • Mª José Mora,
  • Luis Borderias Clau,
  • Lourdes Arizón Mendoza,
  • Sandra García,
  • Juan AR Miranda,
  • Julián Grande Gutiérrez,
  • Jesús Agustín Manzano,
  • Manuel González,
  • Milagros Rosales,
  • José AF Villar,
  • Ana Priegue,
  • Isabel Portela Ferreño,
  • Cecilia Mouronte Roibás,
  • Sara Fernández García,
  • Rocío Cordova Díaz,
  • Nuria Toledo Pons,
  • Margalida Llabrés,
  • José MM Trigo,
  • Marta Forner,
  • Pablo Cubero,
  • Elisabet Vera,
  • Mª BP Albero,
  • Noelia González García,
  • Agustín Valido Morales,
  • Carolina Panadero,
  • Cristina Benito Bernáldez,
  • Maria Velarde,
  • Antonio Santa Cruz Siminiani,
  • Carlos Castillo Quintanilla,
  • Rocío Ibáñez Meléndez,
  • José JM Garcerán,
  • Desirée Lozano Vicente,
  • Pedro García Torres,
  • Maria del Mar Valdivia,
  • Juan PT Tajes,
  • Montserrat Cizur Girones,
  • Carmen Labiano Turrillas,
  • Carlos Ruiz Martínez,
  • Elena Hernando,
  • Elvira Alfaro,
  • José Manuel García,
  • Jorge Lázaro,
  • David Bravo,
  • Laura Hidalgo,
  • Silvia Francisco Terreros,
  • Iñaki Zorrilla,
  • Ainara Alonso Colmenero,
  • Cristina Martínez González,
  • Susana Margon,
  • Rosirys Guzman Taveras,
  • Alicia Álvarez,
  • José RA Balbín,
  • Juan Agüero Calvo,
  • Jaume Ferrer Sancho,
  • Esther Rodríguez González,
  • Eduardo Loeb,
  • José LI Alonso,
  • Mª AR García,
  • Juan Abreu González,
  • Candelaria Martín García,
  • Rebeca Muñoz,
  • Haydée Martín García,
  • Miguel AM Muñiz,
  • Andrés AS Antuña,
  • Jesús Allende González,
  • Jose AG Blanco,
  • Fernando JA Navascues,
  • Manuel AV Montes,
  • María Rodríguez Pericacho,
  • Concepción Rodríguez García,
  • Juan DA Mavárez

DOI
https://doi.org/10.1136/bmjresp-2022-001468
Journal volume & issue
Vol. 10, no. 1

Abstract

Read online

Background Population distribution of reduced diffusing capacity of the lungs for carbon monoxide (DLCO) in smokers and main consequences are not properly recognised. The objectives of this study were to describe the prevalence of reduced DLCO in a population-based sample of current and former smoker subjects without airflow limitation and to describe its morphological, functional and clinical implications.Methods A sample of 405 subjects aged 40 years or older with postbronchodilator forced expiratory volume in 1 s/forced vital capacity (FVC) >0.70 was obtained from a random population-based sample of 9092 subjects evaluated in the EPISCAN II study. Baseline evaluation included clinical questionnaires, exhaled carbon monoxide (CO) measurement, spirometry, DLCO determination, 6 min walk test, routine blood analysis and low-dose CT scan with evaluation of lung density and airway wall thickness.Results In never, former and current smokers, prevalence of reduced DLCO was 6.7%, 14.4% and 26.7%, respectively. Current and former smokers with reduced DLCO without airflow limitation were younger than the subjects with normal DLCO, and they had greater levels of dyspnoea and exhaled CO, greater pulmonary artery diameter and lower spirometric parameters, 6 min walk distance, daily physical activity and plasma albumin levels (all p<0.05), with no significant differences in other chronic respiratory symptoms or CT findings. FVC and exhaled CO were identified as independent risk factors for low DLCO.Conclusion Reduced DLCO is a frequent disorder among smokers without airflow limitation, associated with decreased exercise capacity and with CT findings suggesting that it may be a marker of smoking-induced early vascular damage.Trial registration number NCT03028207.